Pre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient cd8 t-cell memory and recall responses

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Steffensen, Maria Abildgaard ^a   Jensen, Benjamin Anderschou Holbech ^a   Holst, Peter Johannes ^a   Bassi, Maria Rosaria ^a   Christensen, Jan Pravsgaard ^a   Thomsen, Allan Randrup ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VIRUS ANTIBODY;

ADENOVIRUS 5; ADENOVIRUS INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; FEMALE; IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; REVACCINATION; TRANSGENE; VECTOR IMMUNITY; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; C57BL MOUSE; FLOW CYTOMETRY; GENE VECTOR; IMMUNOLOGY; PHYSIOLOGY;

ADENOVIRIDAE; ANIMALIA; MUS;

ADENOVIRIDAE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GENETIC VECTORS; MICE; MICE, INBRED C57BL;

EID: 84859715603     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034884     Document Type: Article

References (32)

1. Barouch DH, McKay PF, Sumida SM, Santra S, Jackson SS, et al. (2003) Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77: 8729-8735.
2. Pichla-Gollon SL, Lin SW, Hensley SE, Lasaro MO, Herkenhoff-Haut L, et al. (2009) Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. J Virol 83: 5567-5573 JVI.00405-09 [pii];10.1128/JVI.00405-09 [doi].
3. Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, et al. (2004) Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 78: 2666-2673.
4. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, et al. (2003) Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77: 799-803.
5. Casimiro DR, Tang A, Chen L, Fu TM, Evans RK, et al. (2003) Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77: 7663-7668.
6. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, et al. (2010) International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28: 950-957 S0264-410X(09)01728-9 [pii];10.1016/j.vaccine.2009.10.145 [doi].
7. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, et al. (2011) International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine S0264-410X(11)00735-3 [pii];10.1016/j.vaccine.2011.05.025 [doi].
8. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, et al. (2005) Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174: 7179-7185 174/11/7179 [pii].
9. Osada T, Yang XY, Hartman ZC, Glass O, Hodges BL, et al. (2009) Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 16: 673-682 cgt200917 [pii];10.1038/cgt.2009.17 [doi].
10. Holst PJ, Orskov C, Thomsen AR, Christensen JP, (2010) Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination. J Immunol 184: 4431-4439 jimmunol.0900537 [pii];10.4049/jimmunol.0900537 [doi].
11. Holst PJ, Sorensen MR, Mandrup Jensen CM, Orskov C, Thomsen AR, et al. (2008) MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J Immunol 180: 3339-3346 180/5/3339 [pii].
12. Lindsay RW, Darrah PA, Quinn KM, Wille-Reece U, Mattei LM, et al. (2010) CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling. J Immunol 185: 1513-1521 jimmunol.1000338 [pii];10.4049/jimmunol.1000338 [doi].
13. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, et al. (2004) Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172: 6290-6297.
14. Becker TC, Noel RJ, Coats WS, Gomez-Foix AM, Alam T, et al. (1994) Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol 43 Pt A: 161-189.
15. Mizuguchi H, Kay MA, (1998) Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 9: 2577-2583 10.1089/hum.1998.9.17-2577 [doi].
16. Mizuguchi H, Kay MA, (1999) A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 10: 2013-2017 10.1089/10430349950017374 [doi].
17. Battegay M, Cooper S, Althage A, Banziger J, Hengartner H, et al. (1991) Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J Virol Methods 33: 191-198.
18. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, et al. (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77-92 S0022-1759(98)00204-X [pii].
19. Thomsen AR, Marker O, (1988) The complementary roles of cellular and humoral immunity in resistance to re-infection with LCM virus. Immunology 65: 9-15.
20. Holst PJ, Christensen JP, Thomsen AR, (2011) Vaccination against lymphocytic choriomeningitis virus infection in MHC class II-deficient mice. J Immunol 186: 3997-4007 jimmunol.1001251 [pii];10.4049/jimmunol.1001251 [doi].
21. Holst PJ, Sorensen MR, Mandrup Jensen CM, Orskov C, Thomsen AR, et al. (2008) MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J Immunol 180: 3339-3346 180/5/3339 [pii].
22. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, Harris-McCoy KC, Hensley SE, et al. (2007) Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110: 1916-1923 blood-2007-02-062117 [pii];10.1182/blood-2007-02-062117 [doi].
23. Yang TC, Millar J, Groves T, Grinshtein N, Parsons R, et al. (2006) The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J Immunol 176: 200-210 176/1/200 [pii].
24. Bachmann MF, Wolint P, Schwarz K, Jager P, Oxenius A, (2005) Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol 175: 4686-4696 175/7/4686 [pii].
25. Cui W, Kaech SM, (2010) Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol Rev 236: 151-166 IMR926 [pii];10.1111/j.1600-065X.2010.00926.x [doi].
26. Gall J, Kass-Eisler A, Leinwand L, Falck-Pedersen E, (1996) Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 70: 2116-2123.
27. Gall JG, Crystal RG, Falck-Pedersen E, (1998) Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J Virol 72: 10260-10264.
28. Roy S, Shirley PS, McClelland A, Kaleko M, (1998) Circumvention of immunity to the adenovirus major coat protein hexon. J Virol 72: 6875-6879.
29. Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, et al. (2002) Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol 76: 12775-12782.
30. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, et al. (2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441: 239-243 nature04721 [pii];10.1038/nature04721 [doi].
31. Finn OJ, (2008) Cancer immunology. N Engl J Med 358: 2704-2715 358/25/2704 [pii];10.1056/NEJMra072739 [doi].
32. Pellegrini M, Mak TW, (2010) Tumor immune therapy: lessons from infection and implications for cancer- can IL-7 help overcome immune inhibitory networks? Eur J Immunol 40: 1852-1861 10.1002/eji.201040603 [doi].